Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1635)	12/19/2005 7:01:35 PM
From: sammaster	Read Replies (1) \| Respond to of 1826

hospitals get paid a "case rate" for a diagnosis...fee for service is getting much more rare for hospitals.. so if patient was admitted with nausea and vomitting with dehydration post chemo then they would get a fixed rate for that diagnosis.. best for them to use zofran over aloxi if efficacy is only slightly inferior but costs much less... thats why you also see substitution by hospital pharmacies by fairly equivalent ace inhibitors or lipitor/zocor/crestor